Tüdőrák: nyitott vizsgálatok itt: Románia

55 nyitott vizsgálatnak van helyszíne itt: Románia. Regiszteradat; hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Kísérleti kezelés · 3. fázis · Bristol-Myers Squibb
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Memorial Healthcare International S R L, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Institutul Regional de Oncologie Iasi, Iași · Spitalul Municipal Ploiesti, Ploieşti
Regiszter frissítve: 2026-11-09
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Medicover S.R.L., Bucharest · Institutul Regional de Oncologie Iasi, Iași · Sigmedical Services S.R.L., Suceava · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-11-09
NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Kísérleti kezelés · 3. fázis · Amgen
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Spitalul Universitar de Urgență București, Bucharest · Medisprof S.R.L., Cluj-Napoca · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Institutul Regional de Oncologie Iasi, Iași · Spitalul Municipal Ploiesti, Ploieşti · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-11-06
NCT07284121
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Kutatás · Hoffmann-La Roche
Spitalul Clinic de Urgenta Prof. Dr. Agrippa Ionescu, Bucharest · Institut Oncologic Prof. Dr. Alexandru Trestioreanu, Bucharest · Institutul Clinic Fundeni Bucuresti, Bucharest · Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. Octavian Fodor, Cluj-Napoca · Spitalul Clinic Jude?ean de Urgen?? Sfântul Apostol Andrei Galati;oncology, Galati · Institutul Regional de Oncologie Iasi, Iași · Spitalul Municipal Ploiesti, Ploieşti · Spitalul Județean de Urgență Satu Mare, Satu Mare · Oncomed SRL, Timișoara
Regiszter frissítve: 2026-11-06
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Kísérleti kezelés · 3. fázis · Bristol-Myers Squibb
Centrul De Diagnostic Si Tratament Provita S.A., Bucharest · Spitalul Universitar de Urgență București, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Centrul De Oncologie-Euroclinic S.R.L., Iasi · Institutul Regional de Oncologie Iasi, Iași · Asociatia Oncohelp, Timișoara
Regiszter frissítve: 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Kísérleti kezelés · 3. fázis · Eli Lilly and Company
Gral Medical S.R.L, Bucharest · Memorial Healthcare International S R L, Bucharest · Lotus Med S.R.L., Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Ovidius Clinical Hospital S.R.L, Ovidiu · Oncocenter Oncologie Clinica S.R.L, Timișoara · Oncomed SRL, Timișoara
Regiszter frissítve: 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Kísérleti kezelés · 3. fázis · Bayer
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · CardioMed S.R.L., Cluj-Napoca · Oncolab S.R.L., Craiova · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Ovidius Clinical Hospital S.R.L, Ovidiu · Oncocenter Oncologie Clinica S.R.L, Timișoara
Regiszter frissítve: 2026-11-04
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Kísérleti kezelés · 3. fázis · Eli Lilly and Company
SC Memorial Healthcare International SRL, Bucharest · Lotus Med, Bucharest · Institutul Oncologic, Cluj-Napoca · Ovidius Clinical Hospital OCH, Ovidiu
Regiszter frissítve: 2026-11-04
NCT06303505
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Kísérleti kezelés · 1/2. fázis · Gilead Sciences
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca
Regiszter frissítve: 2026-11-03
NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Kísérleti kezelés · 2/3. fázis · Eikon Therapeutics
Medicover Hospitals S.R.L., Bucharest · Medisprof S.R.L., Cluj-Napoca
Regiszter frissítve: 2026-11-03
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Kísérleti kezelés · 2/3. fázis · BioNTech SE
Spitalul Clinic Colțea, Bucharest · Gral Medical S.R.L, Bucharest · Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Medisprof S.R.L., Cluj-Napoca · CardioMed S.R.L., Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Onco Clinic Consult S.A., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Centrul De Oncologie-Euroclinic S.R.L., Iasi · Institutul Regional de Oncologie Iasi, Iași · Ovidius Clinical Hospital S.R.L, Ovidiu · Spitalul Municipal Ploiesti, Ploieşti · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-11-02
NCT06745908
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Kísérleti kezelés · 3. fázis · ImmunityBio, Inc.
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Medisprof S.R.L., Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Ovidius Clinical Hospital S.R.L, Ovidiu · Oncocenter Oncologie Clinica S.R.L, Timișoara
Regiszter frissítve: 2026-11-02
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Kísérleti kezelés · 3. fázis · Boehringer Ingelheim
Memorial Healthcare International S R L, Bucharest · Lotus Med S.R.L., Bucharest · Ovidius Clinical Hospital S.R.L, Ovidiu · Polaris Medical S.A., Suceagu
Regiszter frissítve: 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Kísérleti kezelés · 2/3. fázis · Mirati Therapeutics Inc.
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Medisprof S.R.L., Cluj-Napoca · Radiotherapy Center Cluj S.R.L., Floresti · Centrul De Oncologie-Euroclinic S.R.L., Iasi · Oncocenter Oncologie Clinica S.R.L, Timișoara
Regiszter frissítve: 2026-10-30
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Kísérleti kezelés · 3. fázis · AbbVie
Centrul Medical De Diagnostic Si Tratament Ambulator Neomed S.R.L., Brasov · CardioMed S.R.L., Cluj-Napoca · Oncolab S.R.L., Craiova · Institutul Regional de Oncologie Iasi, Iași · Pelican Impex S.R.L., Oradea · Radiology Therapeutic Center S.R.L., Otopeni · Sigmedical Services S.R.L., Suceava · Oncocenter Oncologie Clinica S.R.L, Timișoara
Regiszter frissítve: 2026-10-29
NCT06422143
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Onco Card S.R.L., Brasov · Lotus Med S.R.L., Bucharest · Medicover S.R.L., Bucharest · CardioMed S.R.L., Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Clinica Polisano S.R.L., Sibiu · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-10-29
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Kísérleti kezelés · 3. fázis · Boehringer Ingelheim
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova
Regiszter frissítve: 2026-10-28
NCT06772623
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Kísérleti kezelés · 1/2. fázis · AbbVie
Spitalul Clinic Colțea, Bucharest · Mnt Healthcare Europe S.R.L., Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Clinica Polisano S.R.L., Sibiu
Regiszter frissítve: 2026-10-27
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Kísérleti kezelés · 3. fázis · Mirati Therapeutics Inc.
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Memorial Healthcare International S R L, Bucharest · CardioMed S.R.L., Cluj-Napoca · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Affidea Romania S.R.L., Constanta · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Centrul De Oncologie-Euroclinic S.R.L., Iasi · Institutul Regional de Oncologie Iasi, Iași · Ovidius Clinical Hospital S.R.L, Ovidiu · Spitalul Municipal Ploiesti, Ploieşti · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-10-27
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Onco Card S.R.L., Brasov · Mnt Healthcare Europe S.R.L., Bucharest · Centrul De Diagnostic Si Tratament Provita S.A., Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Sigmedical Services S.R.L., Suceava · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-10-26
NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Onco Card S.R.L., Brasov · Mnt Healthcare Europe S.R.L., Bucharest · Delta Health Care S.R.L, Bucharest · Spitalul Clinic Colțea, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Spitalul Municipal Ploiesti, Ploieşti
Regiszter frissítve: 2026-10-26
NCT07246863
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Kísérleti kezelés · 2. fázis · CatalYm GmbH
Centrul De Oncologie SF Nectarie S.R.L., Craiova · Clinica Polisano S.R.L., Sibiu · Asociatia Oncohelp, Timișoara
Regiszter frissítve: 2026-10-26
2023-509340-10-00
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Kísérleti kezelés · 3. fázis · OSE Immunotherapeutics
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Oncomed S.R.L., Timisoara
Regiszter frissítve: 2026-10-23
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Kísérleti kezelés · 3. fázis · Daiichi Sankyo
Delta Health Care S.R.L, Bucharest · Spitalul Clinic Colentina Bucuresti, Bucharest · Memorial Healthcare International S R L, Bucharest · Spital Clinic Militar De Urgenta Dr. Constantin Papilian Cluj Napoca, Cluj-Napoca · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Institutul Regional de Oncologie Iasi, Iași · Radiology Therapeutic Center S.R.L., Otopeni · Spitalul Municipal Ploiesti, Ploieşti
Regiszter frissítve: 2026-10-23
NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Kísérleti kezelés · 2/3. fázis · Bristol-Myers Squibb
Centrul De Diagnostic Si Tratament Provita S.A., Bucharest · Spitalul Clinic Colentina Bucuresti, Bucharest · Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest · Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul De Oncologie SF Nectarie S.R.L., Craiova · Radiotherapy Center Cluj S.R.L., Floresti · Centrul De Oncologie-Euroclinic S.R.L., Iasi · Institutul Regional de Oncologie Iasi, Iași · Radiology Therapeutic Center S.R.L., Otopeni · Spitalul Municipal Ploiesti, Ploieşti
Regiszter frissítve: 2026-10-23

Minden vizsgálat (Tüdőrák) és a térkép

Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.

Hibát jelzek